Peptide for promoting mucous membrane permeation and composition containing same

Abstract

A peptide and a peptide multimer according to the present invention serve to control tight bonding between cells, and thereby facilitate the absorption, through a mucous membrane, of an active ingredient of co-administered drugs and the like. Thus, the bioavailability of the active ingredient can be significantly improved, and as a result, the therapeutic effect of the active ingredient can be significantly improved.

The invention claimed is: 
     
       1. A method for promoting mucous membrane permeation of an active ingredient, the method comprising a step of administering a composition together with the active ingredient to a subject, wherein the composition comprises at least one peptide selected from the group consisting of: a peptide comprising an amino acid sequence represented by SEQ ID NO: 1; a peptide comprising an amino acid sequence represented by SEQ ID NO: 2; a peptide comprising an amino acid sequence represented by SEQ ID NO: 3; a peptide comprising an amino acid sequence represented by SEQ ID NO: 4; a peptide comprising an amino acid sequence represented by SEQ ID NO: 5; a peptide comprising an amino acid sequence represented by SEQ ID NO: 12; a peptide comprising an amino acid sequence represented by SEQ ID NO: 14; and a peptide comprising an amino acid sequence represented by SEQ ID NO: 15. 
     
     
       2. The method of  claim 1 , wherein the composition further comprises a pharmaceutically acceptable additive or adjuvant. 
     
     
       3. The method of  claim 1 , wherein the mucous membrane is a mucous membrane in which a tight junction is expressed. 
     
     
       4. The method of  claim 3 , wherein the mucous membrane is a mucous membrane of small intestine, nasal cavity, oral cavity, skin, lung, vagina, rectum or colon. 
     
     
       5. The method of  claim 1 , wherein the active ingredient is fexofenadine, cyclophosphorin A, acyclovir, docetaxel, doxorubicin, leuprorelin, exedin, mannitol, atenolol or rutin. 
     
     
       6. The method of  claim 1 , wherein the active ingredient is fexofenadine. 
     
     
       7. A formulation comprising at least one peptide selected from the group consisting of: a peptide comprising an amino acid sequence represented by SEQ ID NO: 1; a peptide comprising an amino acid sequence represented by SEQ ID NO: 2; a peptide comprising an amino acid sequence represented by SEQ ID NO: 3; a peptide comprising an amino acid sequence represented by SEQ ID NO: 4; a peptide comprising an amino acid sequence represented by SEQ ID NO: 5; and a peptide comprising an amino acid sequence represented by SEQ ID NO: 12; a peptide comprising an amino acid sequence represented by SEQ ID NO: 14; and a peptide comprising an amino acid sequence represented by SEQ ID NO: 15, and an active ingredient. 
     
     
       8. The formulation of  claim 7 , wherein the formulation is formulated for administering enterally, nasally, oromucosally, transdermally, transpulmonarily, rectally or vaginally. 
     
     
       9. The formulation of  claim 7 , wherein the formulation further comprises a pharmaceutically acceptable additive or adjuvant.